Welcome to AMYPAD!

We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. AMYPAD was funded from October 2016 until September 2022.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:

 

→ About Us

 

→ Our papers

 

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD at AD/PD 2023
AMYPAD at AD/PD 2023 24 Nov 2022 Several AMYPAD researchers will be presenting their respective work at the upcoming AD/PD™ Conference......
FDA-CDER-CDRH, SNMMI, and MITA Workshop: Quantitative Brain Amyloid PET Imaging
FDA-CDER-CDRH, SNMMI, and MITA Workshop: Quantitative Brain Amyloid PET Imaging 17 Nov 2022 A workshop on "Quantitative Brain Amyloid PET Imaging in Patients with Alzheimer's Disease" was organised by the US FDA......
AMYPAD presents at the 35th annual EANM congress
AMYPAD presents at the 35th annual EANM congress 24 Oct 2022 We were happy to attend the EANM event in its onsite format......
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.